Triple-Negative Breast Cancer Clinical Trials
3 recruiting
Showing 1–8 of 8 trials
Recruiting
Phase 3
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Triple-Negative Breast Cancer
Merck Sharp & Dohme LLC1,530 enrolled281 locationsNCT06393374
Recruiting
Phase 3
Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer
Triple-Negative Breast Cancer
Fudan University134 enrolled1 locationNCT05806060
Recruiting
Not Applicable
Prospective Biobanking Study in Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response (SCANDARE)
Triple-Negative Breast CancerOvarian CancerCervical Cancer+3 more
Institut Curie1,050 enrolled6 locationsNCT03017573
Recruiting
Phase 2
Triple Negative Breast Cancer and Celecoxib. Pilot Study
Triple-Negative Breast Cancer
Université de Sherbrooke30 enrolled1 locationNCT07104266
Recruiting
Phase 2
A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer
Triple-Negative Breast Cancer
Mabwell (Shanghai) Bioscience Co., Ltd.160 enrolled1 locationNCT06492005
Recruiting
Phase 3
Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.
Triple-Negative Breast Cancer
Fudan University223 enrolled1 locationNCT05760378
Recruiting
The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors
Triple-Negative Breast CancerRenal Cell CarcinomaNon-Small-Cell Lung Carcinoma+1 more
VastBiome800 enrolled1 locationNCT05037825
Recruiting
Phase 1Phase 2
A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast
Triple-Negative Breast Cancer
Jiangxi Provincial Cancer Hospital20 enrolled1 locationNCT04481763